4月10日 - ** 远程医疗公司 LifeMD LFMD.O股价盘前上涨 3% 至 3.48 美元
** 该公司称，4月1日获得美国食品及药物管理局批准后，它将通过其体重管理计划提供Foundayo，一种每日一次的治疗肥胖症的新型口服药物。
** 称Foundayo由礼来LLY.N开发，适用于肥胖或超重并伴有相关健康问题的成年人
** 补充说，现金支付患者的起价为每月149美元；一些商业保险患者可使用礼来储蓄卡支付低至25美元的费用
** 称医疗保险覆盖范围预计将于 7 月开始；处方药将通过 LillyDirect 配送给患者
** 截至上一交易日收盘，该公司股价年累计小幅下跌
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.